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T cells engineered to express CD19-specific chimeric antigen receptors (CARs) have shown breakthrough
clinical successes in patients with B-cell lymphoid malignancies. However, similar therapeutic efficacy of
CAR T cells in solid tumors is yet to be achieved. In this study we systematically evaluated a series of CAR
constructs targeting glypican-3 (GPC3), which is selectively expressed on several solid tumors. We com-
pared GPC3-specific CARs that encoded CD3f (Gz) alone or with costimulatory domains derived from
CD28 (G28z), 4-1BB (GBBz), or CD28 and 4-1BB (G28BBz). All GPC3-CARs rendered T cells highly
cytotoxic to GPC3-positive hepatocellular carcinoma, hepatoblastoma, and malignant rhabdoid tumor cell
lines in vitro. GBBz induced the preferential production of Th1 cytokines (interferon c/granulocyte mac-
rophage colony-stimulating factor) while G28z preferentially induced Th2 cytokines (interleukin-4/
interleukin-10). Inclusion of 4-1BB in G28BBz could only partially ameliorate the Th2-polarizing effect of
CD28. 4-1BB induced superior expansion of CAR T cells in vitro and in vivo. T cells expressing GPC3-
CARs incorporating CD28, 4-1BB, or both induced sustained tumor regressions in two xenogeneic tumor
models. Thus, GBBz CAR endows T cells with superior proliferative potential, potent antitumor activity,
and a Th1-biased cytokine profile, justifying further clinical development of GBBz CAR for immuno-
therapy of GPC3-positive solid tumors.
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INTRODUCTION
CHIMERIC ANTIGEN RECEPTORS (CARs) are hybrid mol-
ecules that combine antigen-binding properties of
monoclonal antibodies (mAb) and signaling ele-
ments of lymphocyte activating molecules. CARs
commonly consist of an antigen-specific single
chain variable fragment (scFv) derived from a mAb,
a spacer, a transmembrane domain, and an endo-
domain containing signaling domains derived from
CD3 zeta (CD3f) and costimulatory molecules such
as CD28 or/and 4-1BB.1,2 T cells genetically en-
gineered to express CARs specific for CD19 have
shown breakthrough clinical successes in patients
with B-cell lymphoid malignancies in recent years.3–9
The technology holds great promise for other types
of cancer, including solid tumors for which conven-
tional cytoreductive therapies often fail.10 However,
the early clinical testing of CAR T cells against solid
tumors has thus far benefited only a small frac-
tion of patients,11–18 highlighting the need to ex-
plore novel antigens and to optimize antigen-specific
CAR design.
Glypican-3 (GPC3), a membrane-bound proteo-
glycan, is expressed in several solid tumors including
hepatocellular carcinoma (HCC), hepatoblastoma,
embryonal sarcoma, malignant rhabdoid tumor
(MRT), yolk sac tumor, Wilm’s tumor, squamous
cell carcinoma of the lung, and liposarcoma.19–29
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GPC3 is an attractive target for immunotherapy
since it is not expressed at detectable levels in
nonmalignant tissues including normal or cirrhotic
liver.19–22 In addition, GPC3 expression in HCC is
associated with significantly worse prognosis even
after complete tumor removal, likely due to GPC3’s
ability to enhance wnt signaling and stimulate
tumor growth.30–37 Two recent early phase clinical
trials tested a GPC3-specific GC33 mAb and dem-
onstrated that targeting GPC3 is safe, well toler-
ated and, depending on the density of GPC3
expression on tumor cells, can achieve significant
antitumor responses in patients with advanced
HCC.38,39
Unlike clinically tested CD19-CARs, which con-
tained either CD28 or 4-1BB co-stimulatory en-
dodomains, the only GPC3-CAR construct reported
contained both CD28 and 4-1BB endodomains.19,40
The inclusion of two endodomains in GPC3-CAR
may be necessary, as in contrast to B-cell malig-
nancies, solid tumors generally express little or no
costimulatory ligands for T cells.41 However, relative
contribution of CD28 and 4-1BB in the effector
functionality of GPC3-CAR T cells remains unknown
and the clear benefit of their combined expression
has not been experimentally established.42–45 In
this study, we systematically evaluated the anti-
tumor properties of T cells expressing GPC3-CARs
encoding CD28, 4-1BB, either endodomain, or
none. In addition to using a well-established HCC
tumor model for evaluating GPC3-CARs, for the
first time we tested the antitumor potential of
GPC3-CAR T cells against MRT. We found that the
costimulatory endodomain composition of the
CARs has significant effect on the cytokine polar-
ization in T cells and 4-1BB induces a Th1 polar-
ized profile. We show that the inclusion of 4-1BB
endodomain alone in GPC3-CAR is sufficient to
generate T cells with enhanced proliferation,
in vivo persistence, and potent therapeutic activ-
ity in xenogeneic tumor models.
MATERIALS AND METHODS
Cell lines
HepG2, Hep3B, A549, G401, and HEK 293T cell
lines were purchased from the American Type
Culture Collection (Manassas, VA). Huh-7 was a
kind gift from Dr. Xiao-Tong Song (Baylor College
of Medicine, Houston, TX), and its identity was
confirmed at the Characterized Cell Line Core
Facility at MD Anderson Cancer Center (Houston,
TX) by short-tandem repeat method. Cell lines
were maintained according to the manufacturer’s
manual. Huh-7 and G-401 cells expressing an en-
hanced green fluorescent protein/firefly luciferase
fusion gene (eGFP.Ffluc)46 were generated by sin-
gle cell cloning after transduction with a retrovirus
encoding eGFP.Ffluc. A549 cells expressing GPC3
(A549.GPC3) were generated by transducing wild
type A549 with a retrovirus encoding GPC3.
Generation of retroviral constructs
A codon-optimized gene was synthesized by
GeneArt (Thermo Fisher Scientific, Waltham, MA)
encoding the GPC3-specific scFv from GC33,47 and
subcloned in frame into retroviral vectors contain-
ing expression cassettes encoding an IgG1 short
hinge, a CD28 transmembrane domain, and CD3f,
CD28f, 4-1BBf, or CD28.4-1BBf signaling do-
mains (Fig. 1). The sequence of each cloned CAR
was verified by sequencing (Seqwright, Houston,
TX). In addition to nontransduced (NT) T cells, dis-
ialoganglioside (GD2)-specific CAR derived from
14g2a.scFv andCD19-specificCARfromFMC63.scFv
containing CD3f and CD28.4-1BB costimulatory en-
dodomains were used as negative controls.48,49
Generation of CAR T cells
Retroviral supernatants were produced by tran-
sient transfection of HEK 293T cells with plasmids
containing one of GPC3-CARs, RDF plasmid en-
coding the RD114 envelope and PegPam3 plasmid
encoding the MoMLV gag-pol as previously de-
scribed.50 Human peripheral blood mononuclear
cells isolated from healthy volunteer donors (Gulf
Coast Regional Blood Center, Houston, TX) were
stimulated with OKT-3/CD28 mAb–coated plates
for 48 h in complete RPMI medium (HyClone RPMI
1640, 10% heat inactivated fetal bovine serum
and 2 mM Glutamax) with interleukin 7 (IL-7;
10 ng/mL) (PeproTech, Rocky Hill, NJ), and IL-15
(5 ng/mL) (Peprotech). IL-7 and IL-15 were used
to optimize CAR T cell expansion.51 After 48 h of
stimulation, cells were transduced on Retronectin
(Kusatsu, Japan)–coated and retroviral particle–
loaded plates and after 48 h cells were removed,
washed, and cultured in IL-7 and IL-15 containing
complete RPMI media for further expansion.
Flow cytometry
For all flow cytometry analyses, FACSArray or
LSR-II instruments were used (BD Biosciences,
Franklin Lakes, NJ). Results were analyzed by
FlowJo (FlowJo, LLC; Ashland, OR). GPC3-CAR
expression was detected by anti-F(ab)2 Alexa Fluor
647–conjugated antibody (Jackson ImmunoResearch,
Cat No. 115-605-006) and anti-goat IgG1 isotype
control (Jackson ImmunoResearch, Cat #: 115-
605-006). GPC3 expression of tumor cell lines was
detected with YP7 mAb 52 provided by Mitchell Ho
(National Institutes of Health, Bethesda, MD).
Cytotoxicity assay
The ability of GPC3-CAR T cells to kill GPC3-
positive tumor cells in vitro was tested in a stan-
dard 4-h chromium 51 (51Cr) release assay as
previously described.53 In brief, target cells were
loaded with 51Cr for 1 h, washed three times, and
mixed with effector cells in 96-well plates at vari-
ous effector to target ratios. Supernatant was col-
lected after 4 h of incubation and radioactivity was
measured to determine specific cytotoxicity.
Multiplex cytokine quantification
Resting GPC3-CAR T cells were co-cultured at a
1:1 ratio with target cells (Supplementary Fig. S1;
Supplementary Data are available online at
www.liebertpub.com/hum) and supernatant was
collected at 24 h. Samples were analyzed with Human
Cytokine/Chemokine Immunoassay Kit (Millipore,
Billerica, MA) according to the manufacturer’s
manual.
In vitro serial killing and CAR
T cell proliferation assay
Tumor cells and effector cells were cocultured
at a 1:1 ratio in complete RPMI without cyto-
kines. Effector cells were counted and re-plated
with fresh tumor cells every 3 days in fresh media.
Carboxyfluorescein succinimidyl ester (Invitrogen,
Carlsbad CA) dilution was measured on day 3 after
first stimulation, as described by Hawkins et al.54,
and 7-amino-actynomycin (BD Biosciences) stain-
ing was performed on day 7 according to the man-
ufacturer’s manual.
Figure 1. Generation of glypican-3 chimeric antigen receptor (GPC3-CAR) T cells. The GPC3-specific single chain variable fragment (scFv) derived from GC33
monoclonal antibodies was cloned in frame into retroviral vectors encoding the immunoglobin 1 (IgG1) short hinge, the CD28 transmembrane domain and a
CD3f signaling domain with or without the costimulatory endodomains derived from CD28, 4-1BB, or their combination. (a) Schematic map of CAR constructs.
(b, c) GPC3-CAR cell surface expression determined by flow cytometry for 1 representative donor and summary data for 10 independent donors (mean and
standard deviation [SD]: Gz, 79.2 – 11.13; G28z, 69.2 – 12.97; GBBz, 73.2 – 14.9; G28BBz, 65.8 – 11.9). Parental T cells are shown as controls. No difference was
detected between the expression levels of GPC3 CARs (analysis of variance [ANOVA]).
Animal models
NOD/SCID/IL2cnull (NSG mice, The Jackson
Laboratory) were maintained at the Small Animal
Core Facility of Texas Children’s Hospital and were
treated according to the protocols approved by
Baylor College of Medicine’s Institutional Biosaf-
ety Committee and Institutional Animal Care and
Use Committee. Twelve-week-old, gender-matched
NSG mice were injected with different tumor cell
lines intraperitoneally (IP) respectively to generate
the tumor-bearing model. To determine the in vivo
proliferation of GPC3-CAR T cells and controls,
T cells were cotransduced with CAR and eGFP.
Ffluc46 constructs and intravenously (IV) injected
into Huh-7 tumor–bearing mice followed by biolu-
minescence imaging every other day. To determine
the antitumor potential of GPC3-CAR T cells, mice
were injected with eGFP.Ffluc expressing Huh-7
(2 · 106 per mouse), G401 (5 · 106 per mouse),
A54955 (2 · 106 per mouse) tumor cells followed by
the IV injection of T cells 5 days (A549), 2 weeks
(Huh-7) or 3 weeks (G401) later, respectively. Tu-
mor bioluminescence was measured by weekly im-
aging and survival was documented for each group.
Statistical analyses
Descriptive analysis was performed to summa-
rize cytokine production and CAR expression on
T cells. Plots of growth curves were generated to
visually illustrate patterns of survival and expan-
sion of CAR T cells. Area under the curve (AUC)
values for CAR T-cell frequencies were calculated
using trapezoidal rule for each treatment group.
The normality assumption was examined, and
if the assumption was in doubt, the data were
transformed when necessary. Statistical compari-
sons were analyzed using ANOVA and t-test with
Bonferroni adjustment as appropriate. Antitumor
efficacy was analyzed using the Kaplan–Meier
method and compared using the Gehan–Breslow—
Wilcoxon test. Statistical analyses were carried out
using GraphPad Prism 5.0 (GraphPad Software)
and SAS 9.4. A p value <0.05 was considered sta-
tistically significant.
RESULTS
GPC3-CARs are stably expressed on T cells
and costimulatory endodomains do not alter
expression levels
The scFv of GC33 mAb was cloned in frame into
SFG gamma-retroviral vectors containing CAR
expression cassettes with CD3f (Gz), CD28.CD3f
(G28z), 4-1BB (GBBz), or CD28.4-1BB.CD3f (G28BBz)
endodomains (Fig. 1a). CD3/CD28-activated T cells
were transduced with RD114-pseudotyped retro-
viral vectors encoding the indicated constructs.
Cell surface expression of CARs was measured by
flow cytometry (Fig. 1b, c). All 4 CARs were stably
expressed on the cell surface of T cells with no
significant difference between constructs. The me-
dian CAR expression was 79.2% (range 60–93%)
for Gz, 80% (range 50–85%) for G28z, 80% (range
52–93%) for GBBz and 70% (range 50–81%) for
G28BBz (Fig. 1c). The generated CAR T-cell lines
contained >95% CD3-positive T cells, which were
comprised of CD4- and CD8-positive T-cell subsets
with the same ratio as in NT T cells (Supplemen-
tary Fig. S1).
GPC3-CAR T cells recognize
and kill GPC3-positive tumor cells
To test whether transgenic expression of GPC3-
CARs renders T cells cytotoxic toward GPC3-positive
targets, we performed standard 51Cr-release cyto-
toxicity assays at the indicated effector to target
ratios using GPC3-positive [HepG2 (hepatoblastoma),
Huh-7 (HCC), Hep3B (HCC), G401 (MRT)], GPC3-
negative, unmodified A549 (lung cancer) cells, and
A549 that were genetically modified to express
GPC3 (A549.GPC3, Supplementary Fig. S2, Sup-
plementary Table S1). NT- and GD2-specific CAR-
expressing (CAR-GD2) T cells served as negative
effector controls. GPC3-CAR T cells specifically
killed A549.GPC3 but not unmodified A549 cells,
confirming the specificity of the generated CARs.
Furthermore, GPC3-CAR T cells effectively killed
all other tumor cells (HepG2, Huh-7, Hep3B, G401)
that were GPC3 positive (Fig. 2). CAR-GD2 and NT
T cells did not kill any of the target cells, demon-
strating that the cytolytic activity of T cells de-
pends on the expression of GPC3 on target cells and
GPC3-CARs on T cells.
Costimulation by 4-1BB and CD28 have
opposing effects on Th1 and Th2 cytokine
production by GPC3-CAR T cells
Having estiablished that GPC3-CAR T cells
recognize GPC3-positive target cells in an antigen-
specific manner, we next determined in coculture
assays the ability of GPC3-CAR T cells to secrete
Th1 (interferon gamma [IFNc], granulocyte mac-
rophage colony-stimulating factor [GM-CSF], IL-2)
and Th2 (IL-4, IL-10) cytokines. We used the same
panel of GPC3-positive and GPC3-negative tumor
cells, and effector controls as for the cytotoxicity
assays. GPC3-positive target cells induced cyto-
kine production of GPC3-CAR T cells and not of NT
or CAR-GD2 T cells confirming specificity (Sup-
plementary Fig. S3a, b), and striking differences
were noted in cytokine release pattern dependent
on the costimulatory endodomains of GPC3-CARs.
After controlling for donor-to-donor variation of
absolute amount of cytokine release we found that
4-1BB costimulation induced higher levels of IFN-c
and GM-CSF production compared with CD28
costimulation compared to Gz ( p < 0.05 in 3 of 4 and
2 of 4 tested cell lines, respectively, Fig. 3). In re-
gard to Th2 cytokines, CD28 costimulation induced
significantly more IL-4 and IL-10 production than
4-1BB costimulation ( p < 0.05 in 3 of 4 tested cell
lines for both cytokines, Fig. 3). Thus, CD28 costi-
mulation skews cytokine productions of T cells to-
ward a Th2 pattern, whereas 4-1BB costimulation
enhances Th1 cytokine production. Introducing 4-
1BB costimulation into G28z T cells could not
overcome the Th2 bias of CD28 costimulation, and
G28BBz T cells produced more IL-10 than Gz T
cells for all cell lines tested (Fig. 3).
Costimulation by 4-1BB results in improved
GPC3-CAR T cell survival during serial killing
of tumor cells in vitro
To determine the effect of costimulatory endo-
domains on GPC3-CAR T cell expansion in vitro,
we performed a 7-day proliferation assay using
Figure 2. GPC3-CAR T cells recognize and kill GPC3-positive tumor cells. Tumor cell lysis was measured with standard 4 h chromium 51 (51Cr) release assay at
indicated effector to target ratios against GPC3-positive solid tumor cell lines HepG2, Huh-7, Hep3B, and G401. GPC3-negative A549 cell line served as negative
control, and A549, genetically modified to express GPC3 (A549.GPC3), as positive control. (a–f) Combined results of sux independent experiments. Non-
transduced T cells and T cells expressing CAR-GD2 were used as controls. GPC3-CAR T cells recognized and killed GPC3-positive cell lines (GPC3-CAR T cells
vs. controls: p < 0.001 for all GPC3-positive targets) but did not lyse GPC3-negative A549.
carboxyfluorescein succinimidyl ester–labeled CAR
T cells that were stimulated with GPC3-positive
tumor cells. NT and CAR-GD2 T cells were used
as controls. G28z, GBBz, and G28BBz induced
greater T cell proliferation than did Gz (Fig. 4a) and
increased their viability as judged by 7-amino-
actynomycin staining (Fig. 4b). Next, we performed
co-cultures in which GPC3-CAR T cells were resti-
mulated every 3 days with fresh GPC3-positive
tumor cells in the absence of cytokines. G28z, GBBz,
and G28BBz outperformed Gz as judged by fold-
increase of absolute number of CAR T cells at the
indicated timepoints (Fig. 4c, d; AUC: Gz vs. con-
trols p < 0.001, Gz vs. G28z or GBBz or G28BBz
p < 0.001). GBBz T cells expanded faster and to a
greater extent than G28z T cells (day 7: G28z
mean 3.2, SD 0.021, GBBz mean 6.0, SD 0.25,
G28z vs. GBBz p < 0.001; day 10: G28z mean 4.9,
SD 0.19, GBBz mean 7.2, SD 0.54, G28z vs. GBBz
p < 0.001). No difference was observed between
Figure 3. Differential cytokine production of GPC3-CAR T cells dependent on costimulatory endodomains. GPC3-positive HepG2, Huh-7, Hep3B, and G401 cells
were cocultured with GPC3-CAR T cells for 24 h at 1:1 ratio and indicated cytokine levels in tissue culture supernatant were measured using Luminex. To
correct for donor to donor variability of absolute cytokine concentrations, the data were normalized as a ratio relative to the maximum in each experiment, with
the maximal cytokine level in each experiment being 1 (formula: sample value / maximum value of the experiment for the tested cytokine; 3–5 independent
donors for all GPC3 CAR constructs). Mean and SD are shown. *p < 0.05; **p < 0.01; ***p < 0.001, one-way ANOVA with Bonferoni post-test analysis. ns, not
significant ( p ‡ 0.05).
GBBz and G28BBz T cells. Thus, inclusion of the
4-1BB endodomain in GPC3-CARs results in en-
hanced T-cell proliferation and improved survival
of T cells after serial killing of GPC3-positive tu-
mor cells in vitro.
Costimulation by 4-1BB results in enhanced
antigen-specific GPC3-CAR T-cell expansion
in vivo
Having established that 4-1BB costimulation
results in superior T-cell proliferation in vitro after
repeated stimulation, we next determined the
ability of GPC3-CAR T cells to expand in vivo.
NSG mice were IP injected with 2 · 106 Huh-7 cells
followed by the IV injection on day 14 of 5 · 106
GPC3-CAR T cells that were genetically modified
to coexpress eGFP/Ffluc. The eGFP.Ffluc construct
encodes an enhanced Ffluc, which is optimal to
track small number of engineered cells in vivo.46
Ffluc-expressing T cells and CD19-CAR T cells
served as controls. Gz, G28z, GBBz, and G28BBz
T cells expanded in comparison to control T cells
within 3 days post T-cell injection ( p < 0.001;
Fig. 5a, b). After day 3, Gz and G28z T-cell popu-
lations contracted, as judged by a decrease in bio-
luminescence signal, whereas GBBz and G28BBz
T cells continued to expand peaking on day 6 (GBBz
vs. G28z: p < 0.001; G28BBz vs. G28z: p < 0.001)
(Fig. 5c). These results demonstrate that 4-1BB
costimulation provides superior GPC3-CAR T-cell
in vivo expansion.
GPC3-positive tumor xenografts can be completely
eliminated by GPC3-CAR T cells in vivo
To evaluate the in vivo therapeutic potential of
GPC3-CAR T cells, NSG mice were injected with
Figure 4. 4-1BB improves survival of GPC3-CAR T cells after repeated stimulation by GPC3-positive target in vitro. GPC3-positive Huh-7 was cocultured at 1:1
ratio with GPC3-CAR T cells and cells were replated every 3 days with fresh tumor cells without the addition of cytokines. (a) Carboxyfluorescein succinimidyl
ester dilution of proliferating GPC3 CAR T cells on day 3. (b) Staining of GPC3-CAR T cells with 7-amino-actynomycin on day 7. (c) Combined results from four
experiments measuring the absolute number of CAR-positive T cells at indicated time points. For nontransduced T cells, absolute T cell number is shown. Day
7: G28z mean 3.2, SD 0.021; GBBz mean 6.0, SD 0.25; G28z vs. GBBz p < 0.001. Day 10: G28z mean 4.9, SD 0.19; GBBz mean 7.2, SD 0.54; G28z vs. GBBz p < 0.001).
(d) Area under the curve (AUC) of cell number of GPC3 CAR T cells and controls are shown (mean and SD): Gz vs. GBBz p < 0.001; Gz vs. G28BBz p < 0.001; G28z
vs. GBBz p = 0.002; G28z vs. G28BBz p = 0.001.
2 · 106 Huh-7.Ffluc cells IP followed by the IV in-
jection of 1 · 107 Gz, G28z, GBBz, or G28BBz T cells
on day 14. Mice injected with phosphate-buffered
saline, NT or CAR-GD2 T cells served as controls.
GPC3-CAR T cells produced sustained tumor re-
gression as judged by bioluminescence imaging
resulting in a survival advantage in comparison
to control groups (controls vs. GPC3-CAR T cells
p < 0.001; Fig. 6a–c). Since we could not find sig-
nificant differences between GPC3-CAR con-
structs, we decreased the dose of GPC3-CAR T cells
10-fold. Mice that had received T cells expressing
GPC3-CARs with costimulatory endodomains had
significant survival advantage compared with con-
trol groups or Gz ( p < 0.001, p < 0.001, respectively,
Supplementary Fig. S4). However, there were no
significant differences among treatment groups
of G28z, GBBz or G28BBz T cells judged by tumor
bioluminescence or survival of tumor-bearing mice.
To confirm that the observed antitumor activity
depends on the expression of GPC3 on tumor cells,
NSG mice were injected with 2 · 106 A549.Ffluc
cells IV followed by the IV injection of 1 · 107 GBBz,
or NT T cells on day 5. After injection of GPC3-CAR
or NT T cells, tumors continued to grow as judged
by bioluminescence imaging, with no survival
difference between both groups (Supplementary
Fig. S5).
Figure 5. 4-1BB improves the expansion of GPC3-CAR T cells induced by GPC3-positive target in vivo. NOD/SCID/IL2cnull (NSG) mice were injected with 2 · 106
GPC3-positive Huh-7 tumor cells intraperitoneally (IP) followed by injection of 5 · 107 green fluorescent protein/firefly luciferase fusion gene (eGFP.Ffluc)–
expressing GPC3-CAR T cells intravenously (IV) on day 21. Parental T cells and CAR-CD19 T cells coexpressing eGFP.Ffluc served as controls. (a) Serial
bioluminescence images of mice at indicated time points. (b) Mean photon count with SDs of mice groups shown at indicated time points. (c) Bioluminescence
on day 6 of indicated treatment groups. Bioluminescence from each mouse (n = 5 per group) with SD from the mean is shown (Control, 4.01 · 105 – 90.41 · 104;
CD19-CAR, 4.81 · 105 – 1.11 · 105; Gz, 8.63 · 105 – 1.86 · 105; G28z, 3.86 · 106 – 8.41 · 105; GBBz, 1.16 · 107 – 2.5 · 106; and G28BBz, 1.5 · 107 – 2.56 · 106).
*p < 0.05; **p < 0.01; ***p < 0.001, one-way ANOVA with Bonferoni post-test analysis.
To test the ability of GPC3-CAR T cells to elim-
inate another GPC3-positive tumor we focused on
G-401, since compared with other tested tumor cells,
it was the least sensitive to cell-mediated cytotox-
icity and induced the lowest amount of cytokine
production in GPC3-CAR T cells in our in vitro ex-
periments (Figs. 2, 3). On day 21, 5 · 106 G-401.Ffluc
cells were injected IP, followed by the IV injection
of 2 · 106 Gz, G28z, GBBz, or G28BBz T cells
(Fig. 6d). Mice injected with phosphate-buffered
Figure 6. GPC3-CAR T cells eliminate HCC and MRT xenografts in vivo. (a) NSG mice (n = 5 per group) were injected with 2 · 106 GPC3-positive Huh-7.Ffluc tumor
cells IP followed by injection of 1 · 107 GPC3-CAR T cells and controls (parental T cells and CAR-GD2 T cells) IV on day 14. Serial tumor bioluminescence imaging of
mice at indicated time points. (b) Tumor bioluminescence as mean photon count with standard deviations of mice groups. Control groups vs. CAR T cell groups
p < 0.001 in weeks 4 and 5. (c) Kaplan–Meier survival curve of tumor-bearing mice after treatment with GPC3-CAR T cells. Control groups vs. GPC3-CAR T cell
groups p < 0.001 by Gehan-Breslow-Wilcoxon test. (d) NSG mice (n = 4–5 per group) were injected with 5 · 106 GPC3-positive G401.Ffluc tumor cells IP followed by
IV injection of GPC3-CAR T cells and controls (parental T cells and CAR-GD2 T) cells on day 21. Serial tumor bioluminescence imaging of mice at indicated time
points. (e) Mean photon count with standard deviations of mice groups shown at indicated time points. G28z, GBBz, and G28BBz vs. Gz p = 0.0083 (AUC). (f) Survival
of tumor-bearing mice after GPC3 CAR T cell treatment. Control groups vs. GPC3-CAR T cell groups p < 0.001 by Gehan-Breslow-Wilcoxon test.
saline, NT, or CAR-GD2 T cells served as controls.
All GPC3-CAR T cell treated mice had a survival
advantage compared to controls ( p < 0.001) (Fig. 6f).
Injection of G28z, GBBz, and G28BBz T cells re-
sulted in significantly greater reduction in tumor
burden compared with Gz T cells and as judged by
tumor bioluminescence over time (AUC p = 0.0083)
(Fig. 6e). Similar to the Huh-7 xenograft model, we
did not find significant differences between G28z, 4-
1BBz, and G28BBz T cells in regards to antitumor
activity and overall survival (Fig. 6f).
DISCUSSION
The early phase testing of CAR T cells in pa-
tients with solid tumors have generated modest
results compared to results obtained testing CD19-
specific CAR T cells in patients with B-cell leuke-
mias and lymphomas, highlighting the need for
systematic testing and optimization of this tech-
nology for solid tumors. We generated a set of
GPC3-CARs and compared their antitumor poten-
tial against GPC3-positive solid tumors (hepato-
blastoma, HCC, MRT) in vitro and in vivo with the
goal of defining the CARs with the most promising
antitumor properties for further clinical develop-
ment. We found that the inclusion of 4-1BB in
GPC3-CARs induced Th1-like polarization of T-cell
cytokine production and stimulated higher rates of
in vitro proliferation and in vivo expansion com-
pared with CARs with CD28 endodomain or with-
out costimulation. In contrast, the inclusion of
CD28 induced high levels of IL-10. We show that
GPC3-CAR T cells have robust antitumor activity
in two xenogeneic tumor models. In addition to
hepatoblastoma and HCC, we demonstrate for the
first time that malignant rhabdoid tumors can be
effectively targeted with CAR T cells.
Since GPC3 is expressed on several solid tumors
but not expressed on mature healthy tissues, it is
an attractive immunotherapeutic target.19–25,36,37,56
We tested the specificity and antitumor potential
of T cells expressing GPC3-CARs with or without
CD28 and/or 4-1BB costimulatory endodomains.
The generated CAR T cells specifically killed GPC3-
positive tumor cells.
Studies have shown that the inclusion of costi-
mulatory endodomains in CARs can enhance T-cell
IFN-c and IL-2 production.44,49,50,57,58 We noticed
that antigen dependent stimulation through
GPC3-CARs with costimulatory endodomains did
not always result in higher production of cytokines
compared with the first generation GPC3-CAR and
that cytokine production was differentially affected
by CD28 and 4-1BB costimulatory endodomains
within GPC3-CARs. Indeed, the inclusion of 4-1BB
induced significantly higher levels of Th1 cytokines
IFN-c and GM-CSF, whereas the inclusion of CD28
resulted in higher levels of IL-10 and IL-4. Our
group has recently described a similar pattern of
Th1/Th2 polarization of natural killer T (NKT) cells
expressing CAR-GD2s with 4-1BB- or CD28 en-
dodomains.48 However, the preferential induction
of Th2 cytokines by CD28f CARs has not been
previously reported in T cells. When targeting
CD19 or mesothelin with CAR T cells, others have
found that the inclusion of CD28 costimulation in
CARs induced T cells to produce higher amounts of
both Th1 (IFN-c, IL-2, TNF-a, IL-6) and Th2 (IL-4,
IL-10) cytokines compared with 4-1BB.44,49,58 This
suggest that the balance of Th1/Th2 cytokine pro-
duction by T cells after CD28f CAR stimulation
depends on the targeted antigen. Gao et al. reported
promising antitumor activity of a third generation
GPC3-CAR with a CD28 and 41BB costimulatory
endodomains in HCC models.19 Our systematic
testing of GPC3-CARs showed that the inclusion of
4-1BB costimulatory endodomain alone is suffi-
cient to induce similar antitumor responses; how-
ever, it produces a more favorable, Th1 cytokine
release pattern. Thus, to find the construct for
clinical testing, it is necessary to evaluate a panel
of CARs with different costimulatory endodomains
for new target antigens since Th2-biased cyto-
kine production may suppress antitumor immune
responses.59–62
Consistent with other published studies,63,64
we found improved proliferation and expansion of
T cells with the inclusion of costimulatory en-
dodomains in GPC3-CARs. We observed that GBBz
and G28BBz induced superior T-cell expansion
both in vitro and in vivo compared to Gz and G28z.
Clinical testing of CAR T cells have shown that
longer T-cell persistence is associated with better
antitumor effect and overall outcome.6,13 However,
in our xenograft models the improved T-cell ex-
pansion and/or Th1 cytokine profile endowed by
GBBz and G28BBz did not translate into a sur-
vival benefit compared with G28z in treated mice.
This is most likely due to the limitations of NSG
mouse models—foremost, the induction of xenoge-
neic GvHD by mature human T cells and the lack
of an immunosuppressive tumor microenviron-
ment.63,65 Thus, novel models, preferentially im-
mune competent animal models, are needed to
study CAR T-cell/tumor cell interactions in vivo.
However, even immune competent animal models
do not adequately recapitulate ‘‘human tumors.’’
Thus, the definitive answer for choosing GBBz or
G28BBz for later stage clinical testing may have to
come from a clinical trial in which both CARs are
compared within individual patients.66
In conclusion, GPC3-CARs with 4-1BB endo-
domains endow T cells with a Th1-biased cytokine
profile, superior proliferative potential, and po-
tent therapeutic activity in vivo, justifying further
clinical development.
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